CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Collegium Pharmaceutical Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Collegium Pharmaceutical Inc
100 Technology Center Dr
Phone: (781) 713-3699p:781 713-3699 STOUGHTON, MA  02072-4710  United States Ticker: COLLCOLL
Business Summary
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Michael T.Heffernan 59 5/19/2022 10/1/2003
President, Chief Executive Officer, Director Joseph J.Ciaffoni 52 7/1/2018 5/31/2017
Chief Financial Officer, Executive Vice President ColleenTupper 47 5/24/2021 5/24/2021
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
BioDelivery Sciences International, Inc. 4131 Parklake Ave Ste 225 RALEIGH NC United States

Business Names
Business Name
Arius Pharmaceuticals, Inc.
Arius Two, Inc.
BioDelivery Sciences International, Inc.
6 additional Business Names available in full report.

General Information
Number of Employees: 197 (As of 12/31/2023)
Outstanding Shares: 32,705,747 (As of 3/27/2024)
Shareholders: 12
Stock Exchange: NASD
Federal Tax Id: 030416362
Email Address: info@collegiumpharma.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024